Top Globe News – Lifestyle
Author:
Connect Biopharma Holdings Limited
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
April 26, 2026
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
April 1, 2026
Connect Biopharma Announces $20.2 Million Private Placement Financing
March 30, 2026
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
March 30, 2026
Connect Biopharma Announces $20.2 Million Private Placement Financing
March 30, 2026
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
March 30, 2026
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 10, 2026
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 10, 2026